Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
Scott Evans(Harvard University Press), Henry F. Chambers(University of California, San Francisco), David Schoenfeld(Harvard University), Vance G. Fowler(Clinical Research Institute), John H. Powers(Leidos (United States)), W. Charles Huskins(Mayo Clinic), Gene Pennello(United States Food and Drug Administration), Dean Follmann(National Institute of Allergy and Infectious Diseases), Christy Chuang‐Stein(Pfizer (United States)), Sara E. Cosgrove(Johns Hopkins University), Ebbing Lautenbach(Philadelphia University), Daniel B. Rubin(Center for Drug Evaluation and Research)
Cited by 340
Related Papers
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
|Clinical Microbiology Reviews|2015|5.1k
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
|Clinical Infectious Diseases|2011|4.2k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2014|2.7k
Waves of resistance: Staphylococcus aureus in the antibiotic era
|Nature Reviews Microbiology|2009|2.7k